Today: 13 June 2026
Hongkong Land share price up 2%: SGX:H78 in focus ahead of MAS review and Fed week
26 January 2026
2 mins read

Hongkong Land share price up 2%: SGX:H78 in focus ahead of MAS review and Fed week

Singapore, Jan 26, 2026, 15:22 SGT — Regular session

  • Hongkong Land shares climbed roughly 2%, reaching US$8.34 in afternoon trading in Singapore.
  • Ahead of Singapore’s MAS policy review on Thursday and the U.S. Federal Reserve meeting later this week, investors are adjusting their positions.
  • Traders are keeping an eye on Hong Kong property sentiment alongside the company’s ongoing share buybacks.

Shares of Hongkong Land Holdings Limited rose 2.1% to US$8.34 by 3:10 p.m. in Singapore, with roughly 1.68 million shares traded. The stock fluctuated between US$8.20 and US$8.36 during the day. It’s listed on the Singapore Exchange under the ticker H78 as a secondary listing for the group.

This shift is significant because property stocks quickly respond to changes in funding costs and rent signals. Investors are re-evaluating their calculations, especially for prime office spaces in Hong Kong and Singapore, where slight tweaks in rates or demand expectations can drastically affect valuations.

Singapore’s central bank is in the spotlight ahead of Thursday’s review. Reuters reports most economists anticipate the Monetary Authority of Singapore (MAS) will leave policy unchanged, citing steady growth and core inflation near 1%. Edward Lee, chief economist at Standard Chartered, said there’s “no urgency” to move this month but predicts tightening in April once inflation hits its low point. Reuters

Just across the border, optimism is growing around Hong Kong’s housing market, injecting fresh momentum into the property sector. Praveen Choudhary, Morgan Stanley’s head of Asia gaming, Hong Kong, and India property research, believes the market is on the cusp of a new upcycle. He predicts home prices will climb about 10% in 2026. “I’ve never been as convinced as I am today,” Choudhary said. South China Morning Post

Shares of Hong Kong-listed developers gained ground Monday morning. Sun Hung Kai Properties, Hang Lung Properties, and CK Asset all climbed by midday, despite the Hang Seng index wavering without clear direction.

Company-specific updates have been sparse. Hongkong Land’s latest filing revealed it repurchased 180,000 shares on Jan. 23 at an average price of US$8.1789. The firm confirmed these shares will be cancelled. Share buybacks, where companies buy back their own stock, can reduce supply and occasionally bolster prices during quieter trading days.

Policy news came from Hong Kong on Monday as China’s central bank vowed to boost financial market ties between the mainland and the city. It plans to support the offshore yuan market and advance yuan-denominated government bond futures in Hong Kong.

The broader context is shaky. Reuters noted gold surged beyond $5,000 an ounce as investors rushed to safe havens. Markets remained tense ahead of the Fed meeting this week, with currency swings adding to the unease.

The risk is clear: a policy surprise. Should MAS signal a stance tighter than what markets expect, or if the Fed pushes back more aggressively against rate-cut bets, bond yields could jump sharply — a move that usually unsettles property stocks.

In the coming sessions, traders are focused on Thursday’s MAS statement, looking for shifts in tone on inflation and the Singapore dollar policy band. They’ll also be watching to see if Hongkong Land’s rally sticks after the central bank risk fades.

Focus now turns to the company calendar: MarketScreener shows Hongkong Land’s Q4 2025 earnings due March 4. Investors want updates on leasing trends and any moves on capital recycling or share buybacks.

Stock Market Today

  • Ascletis Pharma Stock Falls 41.6% in a Month, Valuation Mixed Amid Losses
    June 13, 2026, 12:37 AM EDT. Ascletis Pharma (SEHK:1672) shares dropped 4.4% last week and 41.6% over the past month, raising questions about its valuation. The stock trades at a price-to-book (P/B) ratio of 4.7x, above the Hong Kong Biotech sector average of 3.2x but below a peer group average of 12.5x, signaling mixed valuation metrics. The company remains unprofitable with a negative return on equity of 18.61%, making earnings-based measures less relevant. While longer-term returns remain positive, recent revenue and net income weaknesses alongside ongoing losses pose risks. Investors are advised to review underlying data carefully before deciding on Ascletis Pharma's stock prospects amid a cautious market sentiment.

Latest articles

SGH Limited Holds Back as ASX 200 Pushes Higher Before FY26 Results

SGH Limited Holds Back as ASX 200 Pushes Higher Before FY26 Results

13 June 2026
SGH closed at A$41.51, up 0.70% but underperformed the S&P/ASX 200’s 1.98% surge, as investors weighed solid cash flow and Boral margin gains against a high 36.03 P/E, mixed demand, and M&A risk; the next key catalyst is FY26 results on August 11, with analysts’ average target at A$47.64, 14.76% above Friday’s close.
NCR Voyix Rallies 10% After Investors Shift on Turnaround Bets

NCR Voyix Rallies 10% After Investors Shift on Turnaround Bets

13 June 2026
NCR Voyix soared 10.25% to $7.85, far outpacing the market, as investors focus on the company’s 2026 cash-flow and earnings targets; the next key catalyst is the Q2 2026 earnings update, with stock valuation appearing low if management delivers on margin and cash-flow goals, but risks remain with declining reported revenue and high debt.
Netflix to Paramount: Your Warner Bros bid “doesn’t pass the sniff test” as takeover clock ticks
Previous Story

Netflix to Paramount: Your Warner Bros bid “doesn’t pass the sniff test” as takeover clock ticks

Lloyds Banking Group share price lifts as profit-target talk grows ahead of results
Next Story

Lloyds Banking Group share price lifts as profit-target talk grows ahead of results

Go toTop